Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
1H-Indole-3-carboxamide, 7-methoxy-2-methyl-1-[2-(4-morpholinyl)ethyl]-N-[(1S,2S,4R)-1,3,3-trim ethylbicyclo[2.2.1]hept-2-yl]- |
EINECS | N/A |
CAS No. | 501927-29-3 | Density | N/A |
PSA | 59.22000 | LogP | 4.74780 |
Solubility | N/A | Melting Point |
N/A |
Formula | C27H39N3O3 | Boiling Point | N/A |
Molecular Weight | 453.625 | Flash Point | N/A |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
7-Methoxy-2-methyl-1-[2-(4-morpholinyl)ethyl]-N-[(1S,2S,4R)-1,3,3 -trimethylbicyclo[2.2.1]hept-2-yl]-1H-indole-3-carboxamide; |
Article Data | 1 |
MN-25 (UR-12) is a drug invented by Bristol-Myers Squibb, that acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB2 receptors with a Ki of 11nM, but 22x lower affinity for the psychoactive CB1 receptors with a Ki of 245nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a Ki of 8nM at CB1 and 29nM at CB2, which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB2 (cf. JWH-018 vs JWH-007, JWH-081 vs JWH-098).
2-methyl derivative; Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, Org 28611, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in JWH-200 or A-796,260. Early compounds such as these have subsequently led to the development of a large number of related indole-3-carboxamide cannabinoid ligands.